Subcutaneous Tarlatamab Shows Favorable Safety and Antitumor Activity in Extensive-Stage Small Cell Lung Cancer
Source Summary
Phase 1b DeLLphi-308 study findings show that subcutaneous tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer. Results were presented at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer.
Why it matters
Favorable safety and preliminary antitumor activity data support continued development of subcutaneous tarlatamab as a potential treatment option for patients with extensive-stage small cell lung cancer.
